Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
← catalyst calendarNCT05060341 · readout ≤ 223 d
Sponsored by MeiraGTx, LLC (industry) · MGTX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
22actual
Sites
4
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-12 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Radiation-induced Xerostomia
Primary outcome
what the primary-completion date above is the date OF• Incidence of AEs, treatment-emergent adverse events (TEAEs), and SAEs
measured 4 years
Permalink · MGTX's whole pipeline · Catalyst calendar · Every registered study · What changed